<DOC>
	<DOCNO>NCT00002764</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . It yet know whether surgery plus combination chemotherapy effective surgery alone treat patient lung metastasis soft tissue sarcoma . PURPOSE : Randomized phase III trial compare effectiveness surgery plus combination chemotherapy surgery alone treat patient soft tissue sarcoma spread lung .</brief_summary>
	<brief_title>Surgery With Without Combination Chemotherapy Treating Patients With Lung Metastases From Soft Tissue Sarcoma</brief_title>
	<detailed_description>OBJECTIVES : I . Compare disease control , overall survival , relapse-free survival patient lung metastasis secondary soft tissue sarcoma treat high-dose doxorubicin ifosfamide without filgrastim ( G-CSF ) metastasectomy vs metastasectomy alone . II . Determine safety morbidity regimen patient . OUTLINE : This randomize , multicenter study . Patients stratify accord location metastasis ( unilateral vs bilateral ) . Patients randomize 1 2 treatment arm . Arm I : Patients assign regimen A B . Regimen A : Patients receive high-dose doxorubicin IV ifosfamide IV continuously day 1 filgrastim ( G-CSF ) subcutaneously day 3-13 . Regimen B : Patients receive chemotherapy without G-CSF . Treatment regimens continue every 3 week 3 course . Patients undergo radical pulmonary metastasectomy via thoracotomy sternotomy wedge resection lobectomy . Patients respond disease metastasectomy receive 2 additional course regimen originally assign . Arm II : Patients undergo radical pulmonary metastasectomy arm I . Patients follow every 3 month 2 year , every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : A total 340 patient ( 170 per treatment arm ) accrue study within approximately 4.5 year .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Pheochromocytoma</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven soft tissue sarcoma pulmonary metastasis radical metastasectomy feasible Eligible subtypes : Malignant fibrous histiocytoma Liposarcoma Synovial sarcoma Malignant paraganglioma Fibrosarcoma Leiomyosarcoma Neurogenic sarcoma Unclassified sarcoma Angiosarcoma ( include hemangiopericytoma ) Miscellaneous sarcoma ( include mixed mesodermal tumor uterus ) Ineligible subtypes : Alveolar rhabdomyosarcoma Kaposi 's sarcoma Rhabdomyosarcoma type Malignant mesothelioma Chondrosarcoma Neuroblastoma Dermatofibrosarcoma Osteosarcoma Epithelioid sarcoma Primitive neuroectodermal tumor Ewing 's sarcoma No extrapulmonary disease Previously treat local recurrence allow Patients primarily metastatic disease must undergo radical treatment primary tumor accord local protocol Reevaluation metastasis require randomization PATIENT CHARACTERISTICS : Age : 16 Performance status : WHO 01 Life expectancy : Not specify Hematopoietic : WBC least 3,000/mm3 Platelet count least 120,000/mm3 Hepatic : Bilirubin great 1.25 time normal Renal : Creatinine great 1.6 mg/dL OR Creatinine clearance least 60 mL/min Cardiovascular : No history cardiovascular disease Other : No severe medical illness ( include psychosis ) No prior concurrent primary malignancy except adequately treat carcinoma situ cervix basal cell carcinoma PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy metastatic disease Prior neoadjuvant adjuvant chemotherapy primary soft tissue sarcoma allow cumulative dose doxorubicin great 200 mg/m2 At least 1 year since prior chemotherapy Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>adult angiosarcoma</keyword>
	<keyword>adult fibrosarcoma</keyword>
	<keyword>adult leiomyosarcoma</keyword>
	<keyword>adult liposarcoma</keyword>
	<keyword>adult neurofibrosarcoma</keyword>
	<keyword>adult synovial sarcoma</keyword>
	<keyword>recurrent adult soft tissue sarcoma</keyword>
	<keyword>adult malignant fibrous histiocytoma</keyword>
	<keyword>adult malignant hemangiopericytoma</keyword>
	<keyword>adult malignant mesenchymoma</keyword>
	<keyword>localize benign pheochromocytoma</keyword>
	<keyword>regional pheochromocytoma</keyword>
	<keyword>lung metastasis</keyword>
	<keyword>stage IV uterine sarcoma</keyword>
	<keyword>recurrent uterine sarcoma</keyword>
	<keyword>uterine leiomyosarcoma</keyword>
	<keyword>endometrial stromal sarcoma</keyword>
	<keyword>ovarian sarcoma</keyword>
	<keyword>clear cell sarcoma kidney</keyword>
	<keyword>stage IV adult soft tissue sarcoma</keyword>
</DOC>